Literature DB >> 1804640

Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicity.

U Christians1, K Kohlhaw, J Budniak, J S Bleck, R Schottmann, H J Schlitt, V M Almeida, M Deters, K Wonigeit, R Pichlmayr.   

Abstract

Blood ciclosporin (Cs) metabolite pattern in 58 liver grafted patients was routinely monitored by HPLC from the first Cs dose after transplantation until discharge from hospital. Eighteen patients with normal kidney function were allocated to Group I and 14 patients in Group II suffered Cs nephrotoxicity during their clinical course. There were no significant differences between both groups in blood Cs level, kidney function before transplantation, liver function or co-administration of other potentially nephrotoxic drugs. A correlation matrix involving both groups showed a significant correlation between the blood concentration of metabolite M1c9 and serum creatinine and urea, and an inverse correlation with creatinine clearance. During a nephrotoxic episode the blood concentrations of metabolites M1c9 and M1A were significantly elevated in patients in Group II. Analysis of the time course revealed significantly higher blood levels of M19 and M1c9 in Group II patients compared with those in Group I for the first 10 days after transplantation. Serum creatinine and urea concentrations remained significantly elevated, the creatinine clearance being significantly reduced throughout the period of observation. The elevated blood concentrations of ciclosporin metabolites M1c9 and M19 during nephrotoxic episodes suggest that these metabolites are associated with ciclosporin nephrotoxicity. It could not be decided if the elevated metabolite concentrations were the result of and/or the reason for impaired kidney function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1804640     DOI: 10.1007/BF00314953

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  29 in total

Review 1.  An appraisal of drug interactions with Sandimmun.

Authors:  I T Cockburn; P Krupp
Journal:  Transplant Proc       Date:  1989-10       Impact factor: 1.066

2.  Association of very high blood levels of cyclosporin metabolites with clinical complications after liver transplantation.

Authors:  K Kohlhaw; K Wonigeit; O Schäfer; B Ringe; H Bunzendahl; R Pichlmayr
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

Review 3.  Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine.

Authors: 
Journal:  Transplant Proc       Date:  1990-06       Impact factor: 1.066

4.  Sandimmun metabolites: their potential to cause adverse reactions in the rat.

Authors:  P Donatsch; U Rickenbacher; B Ryffel; J F Brouillard
Journal:  Transplant Proc       Date:  1990-06       Impact factor: 1.066

5.  Biologic significance of cyclosporine metabolites.

Authors:  B Ryffel; B M Foxwell; M J Mihatsch; P Donatsch; G Maurer
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

6.  Liquid-chromatographic measurement of cyclosporin A and its metabolites in blood, bile, and urine.

Authors:  U Christians; K O Zimmer; K Wonigeit; G Maurer; K F Sewing
Journal:  Clin Chem       Date:  1988-01       Impact factor: 8.327

Review 7.  Cyclosporine drug interactions: a review.

Authors:  N K Wadhwa; T J Schroeder; A J Pesce; S A Myre; C W Clardy; M R First
Journal:  Ther Drug Monit       Date:  1987-12       Impact factor: 3.681

8.  Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies.

Authors:  T G Rosano; M A Pell; B M Freed; M T Dybas; N Lempert
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

9.  Toxicity of cyclosporin metabolites.

Authors:  A Davenport; E J Will; A M Davison; J W Ironside
Journal:  Lancet       Date:  1988-08-06       Impact factor: 79.321

10.  Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA.

Authors:  M R Lucey; J C Kolars; R M Merion; D A Campbell; M Aldrich; P B Watkins
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

View more
  9 in total

Review 1.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

2.  Conversion of cardiac and liver transplant recipients from HPLC and FPIA (polyclonal) to an FPIA (monoclonal) technique for measurement of blood cyclosporin A.

Authors:  J H McBride; S Kim; D O Rodgerson; A Reyes
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

Review 3.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

4.  Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I).

Authors:  Felix C Popp; Barbara Fillenberg; Elke Eggenhofer; Philipp Renner; Johannes Dillmann; Volker Benseler; Andreas A Schnitzbauer; James Hutchinson; Robert Deans; Deborah Ladenheim; Cheryl A Graveen; Florian Zeman; Michael Koller; Martin J Hoogduijn; Edward K Geissler; Hans J Schlitt; Marc H Dahlke
Journal:  J Transl Med       Date:  2011-07-28       Impact factor: 5.531

5.  [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients].

Authors:  H Sperschneider; C Wagner; A Korn; U Christians
Journal:  Med Klin (Munich)       Date:  1997-10-15

6.  CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition.

Authors:  Songmao Zheng; Yasar Tasnif; Mary F Hebert; Connie L Davis; Yoshihisa Shitara; Justina C Calamia; Yvonne S Lin; Danny D Shen; Kenneth E Thummel
Journal:  Transplantation       Date:  2013-03-27       Impact factor: 4.939

Review 7.  Cyclosporin clinical pharmacokinetics.

Authors:  A Fahr
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

8.  Clinical impact of hypercalcemia in kidney transplant.

Authors:  Piergiorgio Messa; Cosimo Cafforio; Carlo Alfieri
Journal:  Int J Nephrol       Date:  2011-06-22

9.  Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients.

Authors:  Ida Robertsen; Pål Falck; Arne K Andreassen; Nina K Næss; Niclas Lunder; Hege Christensen; Lars Gullestad; Anders Asberg
Journal:  Transplant Res       Date:  2013-04-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.